{"entity":{"id":"nct03888105","kind":"trial","name":"A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat","aka":["ELM-2","Odronextamab in relapsed or refractory B-cell non-Hodgkin lymphoma"],"tldr":"A phase 2 trial of Odronextamab in hodgkin lymphoma and non-hodgkin lymphoma, run by Regeneron Pharmaceuticals, active and no longer recruiting.","summary":"A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies is a phase 2 interventional study registered as NCT03888105 by Regeneron Pharmaceuticals, with 515 participants enrolled, started 2019-11-13 and due to reach its primary completion in 2026-06-17. Interventions recorded: Odronextamab. Conditions listed: B-cell Non-Hodgkin Lymphoma (B-NHL). No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03888105","url":"https://clinicaltrials.gov/study/NCT03888105"}],"tags":["ctgov-ingest"],"related":["lymphoma-roadmap","paper-elm-2-odronextamab-follicular-ann-oncol-2024"],"cancers":["hodgkin-lymphoma","non-hodgkin-lymphoma","follicular-lymphoma","dlbcl"],"sections":[],"technologies":["t-cell-engager","bispecific-antibody"],"targets":["cd20","cd3"],"drugs":["odronextamab"],"companies":["regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-elm-2-odronextamab-follicular-ann-oncol-2024"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03888105","phase":"2","setting":"An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","sponsor":"Regeneron Pharmaceuticals","result":"In the follicular lymphoma cohort, objective response 80.0 per cent and complete response 73.4 per cent, with median duration of complete response 25.1 months and median progression-free survival 20.7 months.","started":"2019-11-13","startedType":"actual","yearReported":2024,"enrolled":515,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03888105/","neighbours":{"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}],"paper":[{"id":"paper-elm-2-odronextamab-follicular-ann-oncol-2024","kind":"paper","name":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","route":"/key-papers/paper-elm-2-odronextamab-follicular-ann-oncol-2024/"}],"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"drug":[{"id":"odronextamab","kind":"drug","name":"Odronextamab","route":"/drugs/odronextamab/"}],"company":[{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}]}}